Anna Osamura

Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin

T. Hirano, Toshiyuki Hayashi, Y. Ito, 2017, Cardiovascular Diabetology.

Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency: A randomized prospective pilot study.

T. Hirano, Toshiyuki Hayashi, S. Goto, 2018, Diabetes research and clinical practice.

Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes

T. Hirano, Toshiyuki Hayashi, M. Ohara, 2015, Drugs in R&D.

Risk factors during the early postpartum period for type 2 diabetes mellitus in women with gestational diabetes.

N. Sakamoto, Y. Hiramatsu, Y. Ogawa, 2020, Endocrine journal.

Present status of clinical care for postpartum patients with hypertensive disorders of pregnancy in Japan: findings from a nationwide questionnaire survey

N. Sakamoto, H. Metoki, A. Mito, 2015, Hypertension in pregnancy.

Correction to: Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin

T. Hirano, Toshiyuki Hayashi, Y. Ito, 2017, Cardiovascular Diabetology.